DOCSLIB.ORG

Herpes Viruses (Other Than CMV, EBV, and HHV-8)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Herpes Viruses (Other Than CMV, EBV, and HHV-8) APPENDIX 2 Herpes Viruses (Other Than CMV, EBV, Common Human Exposure Routes: and HHV-8) • Contact with infected human secretions (saliva, semen) most common; aerosols also possible Disease Agent: Likelihood of Secondary Transmission: • Herpes simplex viruses 1 and 2 (HSV-1,2) • Varicella-zoster virus (VZV) • Moderate • Human herpesviruses-6,7 (HHV-6,7) At-Risk Populations: Disease Agent Characteristics: • All populations at risk for infection for most of these • Family: Herpesviridae; Subfamilies: Alphaherpesviri- agents nae (HSV-1,2; VZV), betaherpesvirinae (HHV-6,7); • Typically greater risk of disease in immunocompro- Genus: Simplexvirus (HSV-1,2); Varicellovirus (VZV); mised hosts or following bone marrow or solid organ Roseolovirus (HHV-6,7) transplantation • Virion morphology and size: Enveloped; icosadelta- hedral nucleocapsid symmetry, spherical to pleomor- Vector and Reservoir Involved: phic particles, 160-200 nm in diameter. Between the • Infected humans capsid and the envelope is an amorphous layer of proteins termed the tegument. Blood Phase: • Nucleic acid: Linear, double-stranded DNA about • HSV and VZV viremia in symptomatic neonates, and 125-170 kbp in length immuncompromised hosts is well described. • Physicochemical properties: Nonionic detergents • Viremia in immunocompetent hosts occurs with both solubilize the envelope; virus stable when frozen, primary and recurrent HSV and VZV infection, but for especially at -80°C or below; virus inactivated by UV short intervals and at relatively low levels light, gamma-irradiation, standard disinfectants, and • HHV-6,7 circulates as latent virus in lymphocytes over heating. Herpes viruses do not, in general, survive for the long-term (lifelong) and can reactivate later in life long periods outside the host. and in association with immunosuppression. • Herpesviridae cause primary infection followed by lifelong latency with the opportunity for reactivation Survival/Persistence in Blood Products: of productive infection. ᭺ HSV-1,2 and varicella are latent in nerve cells. • Unknown ᭺ HHV-6,7 are latent in lymphocytes. Transmission by Blood Transfusion: Disease Name: • While the lymphocyte association of HHV-6,7 sug- • Multiple, including oropharyngeal and genital herpes gests the possibility of transfusion transmission, well- (HSV-1,2); varicella (chickenpox), herpes zoster, or documented case reports or series are not available. shingles (VZV); and exanthem subitum or roseola • Case reports of HHV-6 transmission by peripheral infantum (HHV-6,7) blood stem cells have used molecular methods to detect integrated donor HHV-6 DNA in the chromo- Priority Level somes of engrafted donor cells. This appears to be • Scientific/Epidemiologic evidence regarding blood transmission of latent infection rather than of active safety: Theoretical infection. Furthermore, transplant recipients may • Public perception and/or regulatory concern regard- reactivate preexisting HHV-6 infection, thereby con- ing blood safety: Absent founding the evaluation of potential transfusion • Public concern regarding disease agent: Absent transmission. • Although viremia occurs during both primary and Background: reactivation infections with HSV and VZV, transmis- • Primary infections are followed by lifelong latency of sion by blood has never been reported for HSV-1, this family of viruses, which raises the issue of reacti- HSV-2, and VZV. vation syndromes in both healthy and immuno- Cases/Frequency in Population: compromised hosts. • Rates of infection are stable in US population, except • HSV: 50-80% adults seropositive for a marked decrease in the incidence of primary • VZV: Up to 95% seropositive VZV infection with introduction of universal • HHV-6: >90% seropositive immunization. • HHV-7: 70-90% seropositive 96S TRANSFUSION Volume 49, August 2009 Supplement APPENDIX 2 Incubation Period: any of these viruses in the immune compromised host can cause severe disease. • HSV-1,2: 2-12 days • VZV: 10-21 days Mortality: • HHV-6,7: 5-15 days • Rare, except in immunocompromised patients Likelihood of Clinical Disease: Chronic Carriage: • HSV: Mucocutaneous disease (orolabial and genital • Yes; lifetime latency is typical. herpes) common. Severe disease is rare in immuno- competent hosts, but, if it occurs, it can be deadly Treatment Available/Efficacious: (e.g., severe encephalitis). • VZV: Varicella (chickenpox) was previously very • There are a variety of nucleoside analog drugs used to common (about 4 million cases/year in the US before treat herpes virus infections, including acyclogua- recommendations for universal vaccination), but nosine (acyclovir), famciclovir, valacyclovir, ganciclo- rates have fallen 75-85% and continue to decline; vir and valgancylovir, cidofovir, and foscarnet. All of herpes zoster due to reactivation of latent virus con- these drugs suffer from the selection of resistant tinues to increase after age 60 years with lifetime risk herpes mutants. As with HSV, acyclovir (or other ~50% among persons who survive to 85 years (1.7 nucleoside analogs) can be useful, particularly in pre- cases/1000 population in the US) venting VZV disease, and varicella immunoglobulin • HHV-6,7: High in children; prevalent in febrile chil- also can be used. Unlike herpes simplex virus and dren if sought VZV, there are no drugs proven effective for HHV-6 or 7, although there is uncontrolled evidence suggesting Primary Disease Symptoms: that several of the above drugs have promise for • HSV-1 and -2 HHV-6 infections. ᭺ Gingivostomatitis and orolabial ulcers (cold Agent-Specific Screening Question(s): sores) primarily from HSV-1 ᭺ Genital herpes primarily with HSV-2 • No specific question is in use. ᭺ Aseptic meningitis (sometimes recurrent) • Not indicated because transfusion transmission has ᭺ Encephalitis and disseminated infections seen in not been definitively demonstrated neonates and immunocompromised hosts • No sensitive or specific question is feasible. Most • VZV infections are aquired during childhood, and the pre- ᭺ Disseminated rash (chickenpox or varicella) and velance of latent infections is so high as to make ques- dermatomal rash (zoster) tions impractical. ᭺ Widespread visceral dissemination in immuno- compromised hosts Laboratory Test(s) Available: • HHV-6,7 • No FDA-licensed blood donor screening test exists. ᭺ Exanthem subitum (or roseola infantum) is a very common self-limited, benign childhood • Serology, NAT, and cultivation of viruses rash. Nonspecific febrile illness is also frequently Currently Recommended Donor Deferral Period: observed. ᭺ Reactivation of latent HHV-6,7 in immuncom- • No FDA Guidance or AABB Standard exists. promised hosts can result in disseminated infec- • Persons with symptomatic primary genital or orola- tion of multiple organs and is assocatiated with bial HSV may not feel well on the day of donation and poor clinical outcomes, especially in recipients of would often be deferred. hematopoetic transplantation. • Deferral practices for recurrent HSV infection, if reported by the donor, vary by collection facility. Severity of Clinical Disease: • Prudent practice would be to defer prospective donors with primary (chickenpox) or recurrent • Primary infections in well hosts are generally self- (shingles/zoster) varicella until signs and symptoms limited with full recovery. Reactivation of latent infec- are gone. tions with HSV-1 and 2 causes self-limited illness. Reactivation of VZV as shingles generally heals with Impact on Blood Availability: few sequelae but can cause relatively severe disability because of postherpetic neuralgia. HHV-6,7 infec- • Agent-specific screening question(s): Not applicable tions in children are usually benign. Reactivation of • Laboratory test(s) available: Not applicable Volume 49, August 2009 Supplement TRANSFUSION 97S APPENDIX 2 Impact on Blood Safety: 4. Hambleton S. Chickenpox. Curr Opin Infect Dis 2005; 18:235-40. • Agent-specific screening question(s): Not applicable 5. Harel L, Smetana Z, Prais D, Book M, Alkin M, Supaev • Laboratory test(s) available: Not applicable E, Mendelson E, Amir J. Presence of viremia in patients with primary herpetic gingivostomatitis. Clin Leukoreduction Efficacy: Infect Dis 2004;39:636-40. 6. Hellstrom B, Vahlquist B. Experimental inoculation of • Viruses that have a blood phase (HHV-6,7) are typi- roseola infantum. Acta Paediatr 1951;40:189-97. cally present within WBCs; therefore, leukoreduction 7. Kempe C. Show EB, Jackson JR, Silver HK. Studies on is likely to be effective by analogy to human cytome- the etiology of exanthema subitum (roseola infan- galovirus. However, cell-free virus also has been tum). J Pediatr 1950;37:561-8. detected in cases of primary infection in children. 8. Mainka C, Fuss B, Geiger H, Höfelmayr H, Wolff MH. Pathogen Reduction Efficacy for Plasma Derivatives: Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol, 1998;56: • These viruses are primarily WBC associated, but 91-8. plasma viremia may be present. Because these 9. Naraqui S, Jackson GG, Jonasson OM. Viremia with viruses are lipid enveloped and relatively labile, any herpes simplex type 1 in adults. Four non-fatal cases, free virus in plasma should be sensitive to the many one with features of chickenpox. Ann Int Med. 1976; measures used in the fractionation process. 85:165-9. 10. Pellett PE, Roizman B. The family Herpesviridae:a Other Prevention Measures: brief introduction. In: Knipe DM, Howley PM, editors. Fields virology, 5th ed. Philadelphia: Lippincott • None Williams
Load more

Recommended publications
  • Roseola Fact Sheet
    Sixth Disease/ Exanthem Subitum DISTRICT OF COLUMBIA DEPARTMENT OF HEALTH Division of Epidemiology, Disease Surveillance and Investigation 899 N. Capitol Street, NE, Suite 580 Washington, D.C. 20002 202-442-9371 Fax 202-442-8060 * www.dchealth.dc.gov What is Roseola? medications. Frequent hand washing may Roseola is an acute, febrile rash illness caused by a limit transmission (spread). Women who are virus. pregnant and have been exposed to this illness should discuss the exposure with Who gets Fifth Disease? their doctor. Roseola occurs in children usually under four years of age. It is most common in children under the age Should a child with Roseola be excluded of two. from Child-care? Yes, a child with fever and rash should be What are the symptoms of Roseola? excluded from child-care until seen by a The symptoms of roseola include a high fever that health-care provider. The child may return lasts for three to five days. A runny nose, irritability, to child-care once the fever has gone, even if eyelid swelling, and tiredness may also be present. the rash is present. When the fever disappears, a rash appears, mainly on the face and body. How can Roseola be prevented? There is no vaccine or medicine that How is Roseola spread? prevents roseola. Frequent and thorough Roseola is spread from person to person but the hand washing is recommended as a practical exact way is not known. It appears that saliva may be and effective method of preventing most an important way for the spread of the virus.
    [Show full text]
  • Communicable Disease Chart
    COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious;
    [Show full text]
  • THROMBOCYTOPENIA: OUTCOMES of VARICELLA in ADULTS 1Amber Arshad, 2Dr
    IAJPS 2018, 05 (12), 14370-14373 Amber Arshad et al ISSN 2349-7750 CODEN [USA]: IAJPBB ISSN: 2349-7750 INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES http://doi.org/10.5281/zenodo.1976759 Available online at: http://www.iajps.com Research Article THROMBOCYTOPENIA: OUTCOMES OF VARICELLA IN ADULTS 1Amber Arshad, 2Dr. Shafia Masood, 3Dr. Zarwa Shahid 1FMH Collage of Medicine and Dentistry, Lahore-Pakistan 2Holy Family Hospital Rawalpindi 3House Officer, Jinnah Hospital Lahore Abstract: Objectives: The purpose of this research work is to elaborate the seriousness and rate of the low quantity of the platelets in the blood having relation with adult patients suffering of chickenpox. Methodology: This was a descriptive research work carried out in Mayo hospital Lahore and the duration of this research work was from January 2015 to March 2018 in the department of infectious diseases. In this study, record of the demographics, medical data, and blood & biochemical alterations created for each and every patient. The entry of this data carried out on a special organized form. Patients with previous background of CLD (chronic liver disease), drug addicts, HIV patients, blood abnormalities, or consumers of the wine were not the part of this research work. The count of the full blood with count of the platelet conducted with the help of an automated BCM (Beckman Coulter machine). The verification of the haematological results, the patients having low quantity of the platelet underwent PSE (peripheral smear examination). Results: One hundred and ten patients were the participant of this research work. The average age of the patients was 32.9 ± 9.7 years.
    [Show full text]
  • Cutaneous Manifestations of HIV Infection Carrie L
    Chapter Title Cutaneous Manifestations of HIV Infection Carrie L. Kovarik, MD Addy Kekitiinwa, MB, ChB Heidi Schwarzwald, MD, MPH Objectives Table 1. Cutaneous manifestations of HIV 1. Review the most common cutaneous Cause Manifestations manifestations of human immunodeficiency Neoplasia Kaposi sarcoma virus (HIV) infection. Lymphoma 2. Describe the methods of diagnosis and treatment Squamous cell carcinoma for each cutaneous disease. Infectious Herpes zoster Herpes simplex virus infections Superficial fungal infections Key Points Angular cheilitis 1. Cutaneous lesions are often the first Chancroid manifestation of HIV noted by patients and Cryptococcus Histoplasmosis health professionals. Human papillomavirus (verruca vulgaris, 2. Cutaneous lesions occur frequently in both adults verruca plana, condyloma) and children infected with HIV. Impetigo 3. Diagnosis of several mucocutaneous diseases Lymphogranuloma venereum in the setting of HIV will allow appropriate Molluscum contagiosum treatment and prevention of complications. Syphilis Furunculosis 4. Prompt diagnosis and treatment of cutaneous Folliculitis manifestations can prevent complications and Pyomyositis improve quality of life for HIV-infected persons. Other Pruritic papular eruption Seborrheic dermatitis Overview Drug eruption Vasculitis Many people with human immunodeficiency virus Psoriasis (HIV) infection develop cutaneous lesions. The risk of Hyperpigmentation developing cutaneous manifestations increases with Photodermatitis disease progression. As immunosuppression increases, Atopic Dermatitis patients may develop multiple skin diseases at once, Hair changes atypical-appearing skin lesions, or diseases that are refractory to standard treatment. Skin conditions that have been associated with HIV infection are listed in Clinical staging is useful in the initial assessment of a Table 1. patient, at the time the patient enters into long-term HIV care, and for monitoring a patient’s disease progression.
    [Show full text]
  • HIV and the SKIN • Sudden Acute Exacerbations • Treatment Failure DR
    2018/08/13 KEY FEATURES • Atypical presentation of common disorders • Severe or exaggerated presentations HIV AND THE SKIN • Sudden acute exacerbations • Treatment failure DR. FREDAH MALEKA DERMATOLOGY UNIVERSITY OF PRETORIA:KALAFONG VIRAL INFECTIONS EXANTHEM OF PRIMARY HIV INFECTION • Exanthem of primary HIV infection • Acute retroviral syndrome • Herpes simplex virus (HSV) • Morbilliform rash (exanthem) : 2-4 weeks after HIV exposure • Varicella Zoster virus (VZV) • Typically generalised • Molluscum contagiosum (Poxvirus) • Pronounced on face and trunk, sparing distal extremities • Human papillomavirus (HPV) • Associated : fever, lymphadenopathy, pharyngitis • Epstein Barr virus (EBV) • DDX: drug reaction • Cytomegalovirus (CMV) • other viral infections – EBV, Enteroviruses, Hepatitis B virus 1 2018/08/13 HERPES SIMPLEX VIRUS(HSV) • Vesicular eruption due to HSV 1&2 • Primary lesion: painful, grouped vesicles on an erythematous base • HIV: attacks are more frequent and severe • : chronic, non-healing, deep ulcers, with scarring and tissue destruction • CLUE: severe pain and recurrences • DDX: syphilis, chancroid, lymphogranuloma venereum • Tzanck smear, Histology, Viral culture HSV • Treatment: Acyclovir 400mg tds 7-10 days • Alternatives: Valacyclovir and Famciclovir • In setting of treatment failure, viral isolates tested for resistance against acyclovir • Alternative drugs: Foscarnet, Cidofovir • Chronic suppressive therapy ( >8 attacks per year) 2 2018/08/13 VARICELLA • Chickenpox • Presents with erythematous papules and umbilicated
    [Show full text]
  • Experience with Molluscum Contagiosum and Associated Inflammatory Reactions in a Pediatric Dermatology Practice the Bump That Rashes
    STUDY ONLINE FIRST Experience With Molluscum Contagiosum and Associated Inflammatory Reactions in a Pediatric Dermatology Practice The Bump That Rashes Emily M. Berger, MD; Seth J. Orlow, MD, PhD; Rishi R. Patel, MD; Julie V. Schaffer, MD Objective: To investigate the frequency, epidemiol- (50.6% vs 31.8%; PϽ.001). In patients with molluscum ogy, clinical features, and prognostic significance of in- dermatitis, numbers of MC lesions increased during the flamed molluscum contagiosum (MC) lesions, mollus- next 3 months in 23.4% of those treated with a topical cum dermatitis, reactive papular eruptions resembling corticosteroid and 33.3% of those not treated with a topi- Gianotti-Crosti syndrome, and atopic dermatitis in pa- cal corticosteroid, compared with 16.8% of patients with- tients with MC. out dermatitis. Patients with inflamed MC lesions were less likely to have an increased number of MC lesions Design: Retrospective medical chart review. over the next 3 months than patients without inflamed MC lesions or dermatitis (5.2% vs 18.4%; PϽ.03). The Setting: University-based pediatric dermatology practice. GCLRs were associated with inflamed MC lesion (PϽ.001), favored the elbows and knees, tended to be Patients: A total of 696 patients (mean age, 5.5 years) pruritic, and often heralded resolution of MC. Two pa- with molluscum. tients developed unilateral laterothoracic exanthem– like eruptions. Main Outcome Measures: Frequencies, characteris- tics, and associated features of inflammatory reactions Conclusions: Inflammatory reactions to MC, including to MC in patients with and without atopic dermatitis. the previously underrecognized GCLR, are common. Treat- ment of molluscum dermatitis can reduce spread of MC Results: Molluscum dermatitis, inflamed MC lesions, and via autoinoculation from scratching, whereas inflamed MC Gianotti-Crosti syndrome–like reactions (GCLRs) oc- lesions and GCLRs reflect cell-mediated immune re- curred in 270 (38.8%), 155 (22.3%), and 34 (4.9%) of sponses that may lead to viral clearance.
    [Show full text]
  • Oral Manifestations of Systemic Disease Their Clinical Practice
    ARTICLE Oral manifestations of systemic disease ©corbac40/iStock/Getty Plus Images S. R. Porter,1 V. Mercadente2 and S. Fedele3 provide a succinct review of oral mucosal and salivary gland disorders that may arise as a consequence of systemic disease. While the majority of disorders of the mouth are centred upon the focus of therapy; and/or 3) the dominant cause of a lessening of the direct action of plaque, the oral tissues can be subject to change affected person’s quality of life. The oral features that an oral healthcare or damage as a consequence of disease that predominantly affects provider may witness will often be dependent upon the nature of other body systems. Such oral manifestations of systemic disease their clinical practice. For example, specialists of paediatric dentistry can be highly variable in both frequency and presentation. As and orthodontics are likely to encounter the oral features of patients lifespan increases and medical care becomes ever more complex with congenital disease while those specialties allied to disease of and effective it is likely that the numbers of individuals with adulthood may see manifestations of infectious, immunologically- oral manifestations of systemic disease will continue to rise. mediated or malignant disease. The present article aims to provide This article provides a succinct review of oral manifestations a succinct review of the oral manifestations of systemic disease of of systemic disease. It focuses upon oral mucosal and salivary patients likely to attend oral medicine services. The review will focus gland disorders that may arise as a consequence of systemic upon disorders affecting the oral mucosa and salivary glands – as disease.
    [Show full text]
  • Infection Status of Human Parvovirus B19, Cytomegalovirus and Herpes Simplex Virus-1/2 in Women with First-Trimester Spontaneous
    Gao et al. Virology Journal (2018) 15:74 https://doi.org/10.1186/s12985-018-0988-5 RESEARCH Open Access Infection status of human parvovirus B19, cytomegalovirus and herpes simplex Virus- 1/2 in women with first-trimester spontaneous abortions in Chongqing, China Ya-Ling Gao1, Zhan Gao3,4, Miao He3,4* and Pu Liao2* Abstract Background: Infection with Parvovirus B19 (B19V), Cytomegalovirus (CMV) and Herpes Simplex Virus-1/2 (HSV-1/2) may cause fetal loses including spontaneous abortion, intrauterine fetal death and non-immune hydrops fetalis. Few comprehensive studies have investigated first-trimester spontaneous abortions caused by virus infections in Chongqing, China. Our study intends to investigate the infection of B19V, CMV and HSV-1/2 in first-trimester spontaneous abortions and the corresponding immune response. Methods: 100 abortion patients aged from 17 to 47 years were included in our study. The plasma samples (100) were analyzed qualitatively for specific IgG/IgM for B19V, CMV and HSV-1/2 (Virion\Serion, Germany) according to the manufacturer’s recommendations. B19V, CMV and HSV-1/2 DNA were quantification by Real-Time PCR. Results: No specimens were positive for B19V, CMV, and HSV-1/2 DNA. By serology, 30.0%, 95.0%, 92.0% of patients were positive for B19V, CMV and HSV-1/2 IgG respectively, while 2% and 1% for B19V and HSV-1/2 IgM. Conclusion: The low rate of virus DNA and a high proportion of CMV and HSV-1/2 IgG for most major of abortion patients in this study suggest that B19V, CMV and HSV-1/2 may not be the common factor leading to the spontaneous abortion of early pregnancy.
    [Show full text]
  • Hsv1&2 Vzv R-Gene®
    HSV1&2 VZV R-GENE® REAL TIME PCR ASSAYS - ARGENE® TRANSPLANT RANGE The power of true experience HSV1&2 VZV R-GENE® KEY FEATURES CLINICAL CONTEXT 1-5 • Ready-to-use reagents Herpes Simplex Viruses (HSV) 1 and 2 and Varicella-Zoster Complete qualitative and quantitative kit Virus (VZV) are DNA viruses belonging to the Herpesviridae • family. Primary infection is generally limited to the mucous • Simultaneous detection and quantification of membranes and the skin. After primary infection, the virus HSV1 and HSV2 persists in the host by establishing a latent infection. In case • Detection and quantification of VZV of chronic or transient immunosuppression, the virus may Validated on most relevant sample types reactivate to generate recurrent infection. Usually benign, • the infections with these viruses can develop in severe Validated with the major extraction and • clinical forms such as encephalitis, meningitis, retinitis, amplification platforms fulminant hepatitis, bronchopneumonia and neonatal infections. • Designed for low to high throughput analysis Various antivirals have proven their efficacy in treating these pathologies when •Same procedure for all the ARGENE® prescribed early and at appropriate doses. In case of severe infections, it is therefore Transplant kits essential to obtain an early and rapid diagnosis of the infection. TECHNICAL INFORMATION ORDERING INFORMATION HSV1&2 VZV R-GENE® - Ref. 69-014B Parameters HSV1 HSV2 VZV Gene target US7 UL27 gp19 protein CSF, Whole blood, Plasma, BAL, CSF, Whole blood, Plasma, Mucocutaneous
    [Show full text]
  • Clinical Impact of Primary Infection with Roseoloviruses
    Available online at www.sciencedirect.com ScienceDirect Clinical impact of primary infection with roseoloviruses 1 2 1 Brenda L Tesini , Leon G Epstein and Mary T Caserta The roseoloviruses, human herpesvirus-6A -6B and -7 (HHV- infection in different cell types, have the ability to reac- 6A, HHV-6B and HHV-7) cause acute infection, establish tivate, and may be intermittently shed in bodily fluids [3]. latency, and in the case of HHV-6A and HHV-6B, whole virus Unlike other human herpesviruses, HHV-6A and HHV- can integrate into the host chromosome. Primary infection with 6B are also found integrated into the host genome HHV-6B occurs in nearly all children and was first linked to the (ciHHV-6). Integration has been documented in 0.2– clinical syndrome roseola infantum. However, roseolovirus 1% of the general population and along with latency infection results in a spectrum of clinical disease, ranging from has confounded the ability to correlate the presence of asymptomatic infection to acute febrile illnesses with severe viral nucleic acid with active disease [4]. neurologic complications and accounts for a significant portion of healthcare utilization by young children. Recent advances The syndrome known as roseola infantum was reported as have underscored the association of HHV-6B and HHV-7 early as 1809 by Robert Willan in his textbook ‘On primary infection with febrile status epilepticus as well as the cutaneous diseases’ [5]. This clinical entity is also com- role of reactivation of latent infection in encephalitis following monly referred to as exanthem subitum and early pub- cord blood stem cell transplantation.
    [Show full text]
  • Bronchiolitis Obliterans • Mycoplasma Induced Asthma/Wheezing • Resistant Mycoplasma Infection
    CROSS CANADA ROUNDS - Long Case Mandeep Walia Clinical Fellow BC Children’s Hospital 21 June, 2018 Long Case History • 10 Y, Boy Feb 8th • Fever- low-moderate grade, rhinorrhea, cough (dry), mild sore throat • Nausea, non bilious vomiting Day 5- worsening cough -dry, sleep disturbance. • Walk in clinic- no wheeze. Prescribed ventolin. Minimal improvement Day 8- redness eyes, purulent discharge, blisters on lips, ulcers on tongue & buccal mucosa. Difficulty to swallow solids. History- cont • No headache, abnormal movements, visual or hearing loss • No chest pain/stridor/ • No diarrhoea. Vomiting stopped after D3 • No hematuria/dysuria. Feb 17 (D10)- BCCH ED : • concerns for extensive oral mucositis, new onset skin rash. Past Hx • Healthy pregnancy. No complications. • Born by SVD, no neonatal resuscitation/NICU stay. • Recurrent OM- evaluated by ENT-not required myringotomy tubes. • Mild eczema. Development - milestones normal Immunization- upto date Allergies- no known Treatment Hx- Tylenol/benadryl/Ventolin. No antibiotics/NSAIDS FHx- Caucasian descent. unremarkable. Social Hx- active in sports. No exposure to pets/smoke Physical exam • Weight- 37.9kg(77centile) Skin- • HR-96/min, RR-30/min , • pink papules, 2-3mm, central • SPO2 94% RA, T-39.2ᵒc, BP115/64 erosion, about 15-20 on trunk, • HEENT- upper & lower extremities. Sparing palms & soles. • B/L conjunctival injection, • purulent discharge MSK-no arthritis • • Lips, buccal mucosa , soft & hard Perianal skin, glans- normal palate-scattered vesicles & superficial erosions. No crusting (serous/hemorrhagic) • B/L ears-normal • No clubbing/lymphadenopathy Systemic Examination • Respiratory - tachyapnea. No retractions/indrawing. B/L air entry decreased. No wheeze/crackles. • CVS-S1 S2 normal. no murmur • PA- no HSM • Neurological - conscious.
    [Show full text]
  • Where Do We Stand After Decades of Studying Human Cytomegalovirus?
    microorganisms Review Where do we Stand after Decades of Studying Human Cytomegalovirus? 1, 2, 1 1 Francesca Gugliesi y, Alessandra Coscia y, Gloria Griffante , Ganna Galitska , Selina Pasquero 1, Camilla Albano 1 and Matteo Biolatti 1,* 1 Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] (F.G.); gloria.griff[email protected] (G.G.); [email protected] (G.G.); [email protected] (S.P.); [email protected] (C.A.) 2 Complex Structure Neonatology Unit, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] * Correspondence: [email protected] These authors contributed equally to this work. y Received: 19 March 2020; Accepted: 5 May 2020; Published: 8 May 2020 Abstract: Human cytomegalovirus (HCMV), a linear double-stranded DNA betaherpesvirus belonging to the family of Herpesviridae, is characterized by widespread seroprevalence, ranging between 56% and 94%, strictly dependent on the socioeconomic background of the country being considered. Typically, HCMV causes asymptomatic infection in the immunocompetent population, while in immunocompromised individuals or when transmitted vertically from the mother to the fetus it leads to systemic disease with severe complications and high mortality rate. Following primary infection, HCMV establishes a state of latency primarily in myeloid cells, from which it can be reactivated by various inflammatory stimuli. Several studies have shown that HCMV, despite being a DNA virus, is highly prone to genetic variability that strongly influences its replication and dissemination rates as well as cellular tropism. In this scenario, the few currently available drugs for the treatment of HCMV infections are characterized by high toxicity, poor oral bioavailability, and emerging resistance.
    [Show full text]